[The occurrence of systemic candida mycoses in relation to primary disease and pretreatment].
D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D001064:Appendicitis / Q000150:complications; D002177:Candidiasis / Q000150:complications*; D004696:Endocarditis / Q000150:complications; D006345:Heart Septal Defects, Ventricular / Q000150:complications; D006801:Humans; D007951:Leukemia, Myeloid / Q000150:complications; D008103:Liver Cirrhosis / Q000150:complications; D008588:Meningocele / Q000150:complications; D009205:Myocarditis / Q000150:complications; D011704:Pyelonephritis / Q000150:complications; D012141:Respiratory Tract Infections / Q000150:complications; D018805:Sepsis / Q000150:complications; D016135:Spinal Dysraphism / Q000150:complications; D014397:Tuberculosis, Pulmonary / Q000150:complications; D014511:Uremia / Q000150:complications; D014842:von Willebrand Diseases / Q000150:complications
D000900:Anti-Bacterial Agents
Das Auftreten systemischer Candida-Mykosen im Zusammenhang mit Grundkrankheit und Vorbehandlung.